Do Genetic Variants of the Renin-Angiotensin System Predict Blood Pressure Response to Renin-Angiotensin System–Blocking Drugs? A Systematic Review of Pharmacogenomics in the Renin-Angiotensin System

• Published in: Current hypertension reports Vol. 13; no. 5; pp. 356 - 361
• Main Author: Konoshita, Tadashi
• Format: Journal Article
• Language: English
• Published: New York Current Science Inc 01.10.2011; Springer Nature B.V
• Subjects: Angiotensin I - antagonists & inhibitors; Angiotensin I - genetics; Angiotensin II - antagonists & inhibitors; Angiotensin II - genetics; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Cardiology; Family Medicine; General Practice; Genetic Variation; Humans; Hypertension; Hypertension - drug therapy; Hypertension - genetics; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Nephrology; Peptidyl-Dipeptidase A - drug effects; Pharmacogenetics; Polymorphism, Genetic; Primary Care Medicine; Renin-Angiotensin System - drug effects; Renin-Angiotensin System - genetics; Pharmacogenetics; RAS; Genetic variant; Direct renin inhibitor; Angiotensin-converting enzyme inhibitor; Angiotensin receptor blocker; Renin-angiotensin system; Blood pressure response; ARB; Renin; ACEI; Polymorphism; Pharmacogenomics; Responder

The concept of “pharmacogenomics” or “pharmacogenetics” promises to offer the ultimate in personalized medicine, and the renin-angiotensin system (RAS) is one of the most plausible candidates for the application of this approach in the area of hypertension. For the past two decades, genetic variants...